Skip to main content

Table 4 Recommended doses and dose ranges for levomepromazine in palliative sedation (data refer to subcutaneous application)

From: Evidence for the use of Levomepromazine for symptom control in the palliative care setting: a systematic review

Author Year Study design Mean dose (mg/24 h) Dose range (mg/24 h) Findings
Lebon [30] 2010 case study 25 25-100 levomepromazine in combination with midazolam
Alonso-Babarro [31] 2010 retrospective cohort study 125 100-150 indications: pain, delirium
D'Cruz [32] 2009 case report no data no data indication: agitation/delirium
Stephenson [33] 2008 retrospective chart review 9.4 2.5–75 2006 1996 levomepromazine was often used first line, 2006 midazolam was used first line and levomepromazine as an adjunct
75 25–150 1996
Reuzel [34] 2008 survey study no data no data most common indications: pain and dyspnoea
Sykes [46] 2003 retrospective case–control study 125 125-200 indication: continuing agitation
Gambles [36] 2001 descriptive retrospective study no data 6.25-12.5 indication: agitation/restlessness
Morita E [37] 2001 prospective study 50 50  
Fainsinger [38] 2000 prospective observational multicenter study no data no data most common indication: delirium
Chater [39] 1998 survey study 100 50–250  
Stone [40] 1997 retrospective chart review 64 no data levomepromazine was usually prescribed in combination with another sedative
Oliver ) [41] 1985 retrospective chart review no data 37.5-300 indications: confusion/agitation, pain, vomiting (not palliative sedation as main indication)
Mercadante [42] 2011 SR no data 100-150 based on [39]
DeGraeff [43] 2007 SR 64 25-250 based on [39][40, 45, 46]
Morita T [25] 2005 SR no data 5-12,5 guideline is based on a Delphi process conducted by the Sedation Guideline Task Force
Cowan [45] 2001 SR 64 48-600 based on [40, 41]